Royal Pharmaceutical Society (RPS)
The RPS Pharmacogenomics (PGx) Standards Resource supports prescribers to build and expand PGx competence, helping them to prescribe safely and effectively using PGx, ultimately improving patient outcomes through medicines optimisation. It should be used alongside the RPS Prescribing Competency Framework as an additional resource.
The resource can be used by any prescriber, in settings across the UK, at any point in their career to underpin professional responsibility for prescribing when using PGx information. It is for all regulators, professional bodies, education providers and healthcare organisations.
British Pharmacological Society and Royal College of Physicians
Personalised Prescribing – Using pharmacogenomics to improve patient outcomes, a report from the British Pharmacological Society and the Royal College of Physicians published 28 March 2022, calls for pharmacogenomic testing to be integrated fully, fairly and swiftly into the NHS.
Royal College of General Practitioners (RCGP)
The RCGP Genomic Medicine topic guide published in August 2025 explores part of the RCGP curriculum, Being a General Practitioner. It helps understand important issues relating to genomics in primary care by illustrating the key learning points with a case scenario and questions. It also contains tips and advice for learning, assessment and continuing professional development (CPD), including guidance on the knowledge relevant to this area of general practice.
The British Society for Genetic Medicine, Royal College of General Practitioners, Royal Pharmaceutical Society, British Pharmacological Society, UK Clinical Pharmacy Association have produced a position statement on (DTC-GT) direct to consumer genomic testing (DTC-GT) to support healthcare professionals working in primary care and community settings.
Royal College of Psychiatrists
The role of genetic testing in mental health settings report was published in October 2023. It provides clinically relevant summaries of the current evidence base for genetic testing across a range of mental health conditions.
Royal College of Pathologists
Consent and confidentiality in genomic medicine - new guidance for health professionals (rcpath.org)
Guidance on consent and confidentiality has been published by the College, the Royal College of Physicians and the British Society for Genetic Medicine to help healthcare professionals through the complex ethical issues that arise in genomic medicine.
NICE
Familial Hypercholesterolaemia: Nice Guidelines
Familial breast cancer: NICE Guidance
Guidance on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack
Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx)
Universal CYP2C19 genotyping for clopidogrel prescribing
Clopidogrel is a vital antiplatelet agent used widely in the UK to prevent atherothrombotic events. However, because clopidogrel is a prodrug, it requires enzymatic conversion by the CYP2C19 enzyme to become active. Genetic variants in the CYP2C19 gene can significantly reduce or even abolish this conversion, leaving patients with “intermediate” or “poor” metaboliser phenotypes at higher risk of recurrent strokes or heart attacks.
To address this, the Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx) has developed new clinical guidelines to help prescribers integrate pharmacogenetic testing into standard care.
Medicines and Healthcare Products Regulatory Agency (MHRA)
The Yellow Card Biobank is a collaboration between the Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England . Its goal is to improve understanding of how a patient’s genetic makeup may increase their risk of harm from side effects of medications. The Biobank is currently recruiting patients who have experienced side effects from specific medicines for a research project called the Yellow Card Biobank study.
UK Clinical Pharmacy Association (UKCPA)
The UKCPA Handbook of Pharmacogenomics aims to support the use of pharmacogenetic results to optimise medicines by providing healthcare professionals with evidence-based advice and guidance in a simple and easy to use format. It is a free-to-access online resource.
Clinical Pharmacogenetics Implementation Consortium
The Clinical Pharmacogenetics Implementation Consortium is a reputable, internationally recognised, peer reviewed and evidence-based resource. However, be aware it is American and so the recommendations can sometimes be better aligned with FDA-licensed products.
NHS England
NHS England Fit for the Future: 10 Year Health Plan for England
Genomics features prominently in the NHS 10-year Plan. NHSE have predicted that by 2035, genomics could play a role in up to half of all health encounters
NHS England's Genomics Education Programme exists to deliver and advise on learning and development opportunities that prepare current and future NHS professionals to make the best use of genomics in their practice
Nursing and midwifery genomics framework in England
This Nursing and midwifery genomics framework updated in September 2025 illustrates how nurses and midwives should be enabled and empowered to adopt genomics into their clinical practice.
Implementing lynch syndrome testing and surveillance pathways
NHS South East Genomics
The South East Genomics Medicine Service delivers NHS genomic testing across Kent, Medway, Surrey, Sussex and South London covering a population of 8.5 million people.
